

BIO-TECHNE Corp
Form 4
August 11, 2015

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Bazan J. Fernando

(Last) (First) (Middle)

614 MCKINLEY PLACE N.E.

(Street)

MINNEAPOLIS, MN 55413

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol

BIO-TECHNE Corp [TECH]

3. Date of Earliest Transaction
(Month/Day/Year)

08/07/2015

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director ____ 10% Owner
____X____ Officer (give title ____ Other (specify
below) below)

Chief Technical Officer

6. Individual or Joint/Group Filing(Check
Applicable Line)
____X____ Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(D)	Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form
displays a currently valid OMB control
number.**

SEC 1474
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transaction Code	5. Number of Derivative Securities	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
---------------------------------------	------------------------------	---	---	------------------------	--	--	---

Edgar Filing: BIO-TECHNE Corp - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Year)	(Instr. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 76.02								<u>(1)</u>	07/31/2020	Common Stock	10,000
Stock Option (Right to Buy)	\$ 76.02								<u>(2)</u>	07/31/2020	Common Stock	15,000
Stock Option (Right to Buy)	\$ 94.35								<u>(3)</u>	08/12/2021	Common Stock	15,000
Stock Option (Right to Buy)	\$ 108.49	08/07/2015	A	10,000					<u>(4)</u>	08/07/2022	Common Stock	10,000
Stock Options (Right to Buy)	\$ 108.49	08/07/2015	A	5,000					<u>(6)</u>	08/07/2022	Common Stock	5,000
Restricted Stock Units	<u>(5)</u>	08/07/2015	A	800					<u>(6)</u>	<u>(6)</u>	Common Stock	800

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Bazan J. Fernando 614 MCKINLEY PLACE N.E. MINNEAPOLIS, MN 55413			Chief Technical Officer	

Signatures

/s/ Elizabeth M. Dunshee as Attorney-in-Fact for J. Fernando Bazan pursuant to Power of Attorney filed herewith.

08/11/2015

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Vests 3,333 shares on each of 8/1/14 and 8/1/15 and 3,334 shares on 8/1/16.

(2) Vests 3,750 shares on each of 8/1/14, 8/1/15, 8/1/16 and 8/1/17.

(3) Vests 3,750 shares on each of 8/12/15, 8/12/16, 8/12/17 and 8/12/18.

(4) Vests 2,500 shares on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.

(5) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

(6) Vests in full or in part if certain performance goals are achieved during each of the 2016, 2017 and 2018 fiscal years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.